Freestone Grove Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Freestone Grove Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27M	Buy	+339,967	New	+$25.6M	0.17%	176

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Freestone Grove Partners's IONS Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 339,967 shares worth $27M. The stake represents 0.17% of the portfolio and ranks #176 among its holdings.

513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Freestone Grove Partners held 339,967 shares of Ionis Pharmaceuticals worth $27M as of Q2 2026.
Ionis Pharmaceuticals was a new Freestone Grove Partners position in Q2 2026.
Ionis Pharmaceuticals made up 0.17% of Freestone Grove Partners's portfolio in Q2 2026, its #176 holding.
513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.